Isocitrate dehydrogenase 1 (IDH1) monoallelic point mutations define a molecularly distinct glioma subtype, with 90% of IDH1 mutations having an arginine-histidine substitution at position 132. This evidence concerns the gene IDH1 and central nervous system cancer.